EyePoint Pharmaceuticals | November 20, 2021
EyePoint Pharmaceuticals, Inc. a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced the closing of the previously announced underwritten public offering of 5,122,273 shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional 1,095,000 shares of common stock, and pre-funded warrants to purchase up to an aggregate of 3,272,727 shares of its common stock. The shares of common stock were sold at a public offering price of $13.75 per share, and the pre-funded warrants were sold at a purchase price of $13.74 per pre-funded warrant, for aggregate gross proceeds of approximately $115.4 million, before deducting underwriting discounts and commissions and other offering expenses payable by EyePoint. All of the securities were sold by EyePoint.
Cowen and Guggenheim Securities acted as joint book-running managers for the offering. Cantor acted as passive book-running manager for the offering.
EyePoint intends to use the net proceeds from the offering to advance EYP-1901 into and through Phase 2 clinical trials for wet AMD, DR, and RVO, as well as support its earlier stage pipeline development initiatives, and for general corporate purposes.
The securities described above were offered by the Company pursuant to a shelf registration statement on Form S-3 (No. 333-258598) previously filed with the Securities and Exchange Commission (SEC) on August 6, 2021 and declared effective by the SEC on August 11, 2021.
The securities were offered by means of a prospectus supplement and accompanying prospectus relating to the offering that form a part of the registration statement. A final prospectus supplement relating to and describing the terms of the offering was filed with the SEC on November 18, 2021.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq:EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential twice-yearly intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ®, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU®, for the treatment of postoperative inflammation following ocular surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the use of proceeds for the offering and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint’s actual results to be materially different than those expressed in or implied by EyePoint’s forward-looking statements. For EyePoint, this includes stock price volatility and uncertainties relating to the financial markets, the continued impact of the COVID-19 pandemic on EyePoint’s business, the medical community and the global economy, and the impact of general business and economic conditions. More detailed information on these and additional factors that could affect EyePoint’s actual results are described in EyePoint’s filings with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. All forward-looking statements in this news release speak only as of the date of this news release. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Excelra Knowledge Solutions Pvt Ltd | January 19, 2022
Excelra, a leading global Data & Analytics organization, announced the partnership for its Global Online Structure Activity Relationship Database with XtalPi Inc., an AI-based pharmaceutical biotechnology company reinventing the industry's approach to drug research and development with its Intelligent Digital Drug Discovery and Development platform.
Excelra will provide ADMET datasets in the GOSTAR database to XtalPi Inc. as part of the partnership. GOSTAR's ADMET data will power XtalPi's predictive models. The data helps XtalPi with high precision and predictability to confidently tackle clinical failures of new chemical entities. The well-annotated, high-quality ADMET datasets of GOSTAR are built with a proprietary QMS-ISO certified curation process powered by NLP and human intelligence.
GOSTAR provides comprehensive information encompassing over 8 million compounds, manually curated from a variety of sources including patents and journal articles. The database contains over 29 million SAR associated data points. The well-structured relational database can be utilized for diverse applications across various stages of drug discovery and development lifecycle and aids in target validation, hit identification, early lead identification, and optimization.
"In XtalPi Inc., we develop advanced AI-based algorithms to tackle the challenges in the drug design process. The size and quality of datasets are always a big concern for us to build high-accuracy predictive models. That is why we consider GOSTAR as a unique and precious resource. It has millions of data points covering different compounds' ADMET properties and is also trustful, structured, and updated. We highly recommend GOSTAR to whoever is involved in the innovation of drug design methodologies."
Min Xu, Senior Scientist, Research Manager, XtalPi Inc
Norman Azoulay, Product Leader, Excelra, said, "Artificial Intelligence and Machine Learning is bringing a paradigm shift to drug discovery and development. This partnership will help train XtalPi's models to accurately predict efficacy and safety parameters and to ultimately increase the success rate of drug design."
XtalPi is a pharmaceutical technology company that is reinventing the industry's approach to drug research and development with its Intelligent Digital Drug Discovery and Development platform. With tightly interwoven quantum physics, artificial intelligence, and high-performance cloud computing algorithms, XtalPi's platform provides accurate predictions on the physiochemical and pharmaceutical properties of small-molecule candidates for drug design, solid-form selection, and other critical aspects of drug development. XtalPi is dedicated to improving the efficiency, accuracy, and success rate of drug research and development, and contributing to a healthier society worldwide.
Excelra's data and analytics solutions empower innovation in life sciences from molecule to market. The Excelra Edge comes from harmonizing heterogeneous data sets, applying innovative bioinformatics know-how and technologies to accelerate your drug discovery & development with reliable and result-oriented insights. Excelra's GOSTAR is available as an application for users to seek, find, and discover compounds. In addition, it is offered via APIs and as a downloadable dataset to power in-house libraries and machine learning models.
Kairos Pharma, Ltd. | March 15, 2022
Kairos Pharma, Ltd. a privately-held clinical-stage biotechnology company focused on cancer drug resistance and immunotherapy, announced today that its activated T cell therapy, KROS 201, has received FDA approval to move forward with a Phase 1 clinical trial in patients with recurrent glioblastoma. Kairos Pharma is funding the phase I trial, which will occur at Cedars Sinai Medical Center in Los Angeles.
John Yu, M.D., Kairos CEO, commented, "This IND acceptance is the second substantial clinical milestone within the past month as Kairos accelerates toward its clinical goals for 2022. This first-in-man Phase 1 clinical trial will activate T cells against the cancer stem cells at the root of glioblastoma."
"This achievement pushes the envelope of immune therapies designed to target T cells against devastating cancers."
Neil Bhowmick, Ph.D., Kairos Chief Scientific Officer
KROS 201 activated T cells (ATCs) are killer T cells created in cell culture by activating a patient's white blood cells with cytokines or T cell activating signals and priming dendritic cells with antigens specific to glioblastoma cancer stem cells. Patients with recurrent glioblastoma are given the strongly activated T cells intravenously. As a result, cancer stem cells, which are the source of cancer, are killed by these cells.
In February, the FDA granted an IND for a Phase 2 trial of ENV105 with apalutamide, in addition to the planned Phase 1 trial of activated T cell treatment for KROS 201. In 2022, an ENV105 Phase 1 trial with Tagrisso (AstraZeneca) for lung cancer is expected.
Kairos Pharma also published a notice of allowance of their patent Compositions and Methods for Treating Fibrosis by the United States Patent and Trademark Office, which coincides with the advancement of its clinical milestones. The method of treating fibrosis and certain types of cancer, the composition of matter, and the administration of therapy utilizing KROS-401, a cyclic peptide inhibitor of the IL-4 and IL-13 cytokine receptor complex, are all covered by this patent. This drug has been proven to treat fibrosis and cancer by reversing the M1 to M2 immunosuppressive macrophage shift in cancer and fibrosis.
CEO of Kairos Pharma, Dr. John Yu, stated, "This milestone further supports the already substantial and diversified intellectual property portfolio of Kairos and enables the unfettered clinical development of this novel and transformative therapeutic."
Dr. Ramachandran Murali, Kairos VP of Research and Development and inventor of the KROS 401 molecule, commented, "KROS-401, in addition to fibrosis and cancer, opens a new avenue in therapeutic development for neurological disorders such as Alzheimer's disease."